Measuring quality of life and utilities in esophageal cancer

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 2, 2003, Pages 179-188

  McNamee, Paul ^a   Shenfine, Jon ^b   Bond, John ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH TEES   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Esophageal cancer; Health outcomes; Preferences; Quality of life; Utilities

Indexed keywords

CISPLATIN; FLUOROURACIL;

CANCER PALLIATIVE THERAPY; ECONOMIC EVALUATION; ESOPHAGUS CANCER; HEALTH ECONOMICS; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MORBIDITY; MORTALITY; MULTIMODALITY CANCER THERAPY; OUTCOMES RESEARCH; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0037389674     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.2.179     Document Type: Review

References (70)

1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int. J. Cancer 55(6), 891-903 (1993).
2. Dolan K, Sutton R, Walker SJ, Morris AI, Campbell F, Williams EM. New classification of esophageal and gastric carcinomas derived from changing patterns in epidemiology. Br. J. Cancer 80(5-6), 834-842 (1999).
3. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83(10), 2049-2053 (1998).
4. McKinney A, Sharp L, Macfarlane GJ, Muir CS. Esophageal and gastric cancer in Scotland 1960-1990. Br. J. Cancer 71(2), 411-415 (1995).
5. Office for National Statistics. Mortality Statistics. Review of the Registrar General on Deaths by Cause, Sex and Age, in England and Wales 1997. Series DH2 No.24 (Table 3), 96-97 (1997).
6. Earlam R, Cunha-Melo JR. Esophageal squamous cell carcinoma: I. A critical review of surgery. Br. J. Surg. 67(6), 381-390 (1980).
7. Tekkis PP, Kocher HM, Bentley AJ et al. Operative mortality rates among surgeons: comparison of POSSUM and p-POSSUM scoring systems in gastrointestinal surgery. Dis. Colon Rectum 43(11), 1528-1532 (2000).
8. Dresner SM, Lamb PJ, Shenfine J, Hayes N, Griffin SM. Prognostic significance of peri-operative blood transfusion following radical resection for esophageal carcinoma. Eur. J. Surg. Oncol. 26(5), 492-497 (2000).
9. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of esophageal carcinoma. Br. J. Surg. 77(8), 845-857 (1990).
10. Barr H, Krasner N. Prospective quality-of-life analysis after palliative photoablation for the treatment of malignant dysphagia. Cancer 68(7), 1660-1664 (1991).
11. Loizou LA, Grigg D, Atkinson M, Robertson C, Bown SG. A prospective comparison of laser therapy and intubation in endoscopic palliation for malignant dysphagia. Gastroenterology 100(5), 1303-1310 (1991).
12. Blazeby JM, Alderson D, Farndon JR. Quality of life in patients with esophageal cancer. Recent Results Cancer Res. 155, 193-204 (2000).
13. Blazeby JM, Williams MH, Alderson D, Farndon JR. Observer variation in assessment of quality of life in patients with esophageal cancer. Br. J. Surg. 82(9), 1200-1203 (1995).
14. Blazeby JM, Williams MH, Brookes ST, Alderson D, Farndon JR. Quality of life measurement in patients with esophageal cancer. Gut 37(4), 505-508 (1995).
15. Watson A. A study of the quality and duration of survival following resection, endoscopic intubation and surgical intubation in esophageal carcinoma. Br. J. Surg. 69(10), 585-588 (1982).
16. Diamantes T, Mannell A. Esophageal intubation for advanced esophageal cancer: the Baragwanath experience 1977-1981. Br. J. Surg. 70(9), 555-557 (1983).
17. Brunelli C, Mosconi P, Boeri P, et al. Evaluation of quality of life in patients with malignant dysphagia. Tumor 86(2), 134-138 (2000).
18. Loizou LA, Rampton D, Atkinson M, Robertson C, Bown SG. A prospective assessment of quality of life after endoscopic intubation and laser therapy for malignant dysphagia. Cancer 70(2), 386-391 (1992).
19. Blazeby JM, Alderson D, Winstone K et al. Development of an EORTC questionnaire module to be used in quality of life assessment for patients with esophageal cancer. The EORTC Quality of Life Study Group. Eur. J. Cancer 32A(11), 1912-1917, (1996).
20. van Knippenberg FC, Out JJ, Tilanus HW, Mud HJ, Hop WC, Verhage F. Quality of Life in patients with resected esophageal cancer. Soc. Sci. Med. 35(2), 139-145 (1992).
21. McLarty AJ, Deschamps C, Trastek VF, Allen MS, Pairolero PC, Harmsen WS. Esophageal resection for cancer of the esophagus: long-term function and quality of life. Ann. Thor. Surg. 63(6), 1568-1572 (1997).
22. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Healthcare Programmes. Oxford University Press, Oxford, UK (1997).
23. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus (Cochrane Review). In: The Cochrane Library, Issue 1, (2003).
24. Blazeby JM, Farndon JR, Donovan J, Alderson D. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer 88(8), 1781-1787 (2000).
25. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N. Engl. J. Med. 347(21), 1662-1669 (2002).
26. Nicholson D A, Haycox A, Kay C L, Rate A, Attwood S, Bancewicz J. The cost effectiveness of metal esophageal stenting in malignant disease compared with conventional therapy. Clin. Radiol. 54(4), 212-215 (1999).
27. O'Donnell CA, Fullarton GM, Watt E, Lennon K, Murray GD, Moss JG. Randomized clinical trial comparing self-expanding metallic stents with plastic endoprostheses in the palliation of esophageal cancer. Br. J. Surg. 89(8), 985-992 (2002).
28. Stoller JL, Samer KJ, Toppin DI, Flores AD. Carcinoma of the esophagus: a new proposal for the evaluation of treatment. Can. J. Surg. 20(5), 454-459 (1977).
29. Gelfand GA, Finley RJ. Quality of life with carcinoma of the esophagus. World J. Surg. 18(3), 399-405 (1994).
30. Schipper H, Clinch J, Powell V. Definitions and conceptual issues. In: Quality of life assessments in clinical trials. B. Spilker (Ed). New York, USA, Raven Press, 11-24 (1990).
31. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol. Assess. 2(14), 1-74 (1998).
32. McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires. Oxford University Press, Oxford, UK (1996).
33. Karnofsky DA, Abalmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1, 634-656 (1948).
34. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: Reliability, validity and guidelines. J. Clin. Oncology 2, 187-193 (1984).
35. Spitzer WO, Dobson AJ, Chesterman E, Levi J, Shepherd R, Battista RE et al. Measuring the quality of life of cancer patients. J. Chron. Dis. 34, 585-597 (1981).
36. Ware JE, Kosinski M. SF-36® Physical and mental health summary scales: a manual for users of version 1, (2nd Edition). QualityMetric, Inc., Lincoln, RI, USA (2001).
37. Gandek B, Ware Jr J E,Aaronson NK et al. Tests of data quality, scaling assumptions and reliability of the SF- 36 in eleven countries: results from the IQOLA Project. J. Clin. Epidemiol. 51(11), 1149-1158, (1998).
38. Ware Jr J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med. Care 34(3), 220-233 (1996).
39. Brooks R. EuroQOL: the current state of play. Health Pol. 37(1), 53-72 (1996).
40. Wu AW, Jacobson DL, Frick KD, Clark R, Revicki DA, Freedberg KA et al. Validity and responsiveness of the EuroQol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Qual. Life Res. 11(3), 272-283 (2002).
41. Luo N, Chew LH, Fong KY, Koh DR et al. Validity and reliability of the EQ-5D self-report questionnaire in English speaking Asian patients with rheumatic diseases in Singapore. Qual. Life Res. 12(1), 87-92 (2003).
42. Conner-Spady B, Cumming C, Nabholtz J-M, Jacobs P, Stewart D. Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy. Qual. Life Res. 10(6), 479-486 (2001).
43. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Nat. Cancer Inst. 85(5), 365-376 (1993).
44. Farndon MA, Wayman J, Clague MB, Griffin SM. Cost-effectiveness in the management of patients with esophageal cancer. Br. J. Surg. 85(10), 1394-1398 (1998).
45. Sneeuw KC, Aaronson NK, Sprangers MA, Detmar SB, Wever LD, Schornagel JH. Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients. J. Clin. Epidemiol. 51(7), 617-631 (1998).
46. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy (FACT) scale: Development and validation of the general measure. J. Clin. Oncol. 11(3), 570-579 (1993).
47. Brooks JA, Kesler KA, Johnson CS, Ciaccia D, Brown JW. FACT-G: Prospective analysis of quality of life after surgical resection for esophageal cancer: preliminary results. J. Surg. Oncol. 81(4), 185-194 (2002).
48. Kemmler G, Holzner B, Kopp M R et al. Comparison of two quality of life instruments for cancer patients: the Functional Assessment of Cancer Therapy-General and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J. Clin. Oncol. 17, 2932-2940 (1999).
49. Clark A, Fallowfield LJ. Quality of life measurements in patients with malignant disease: a review. J. Royal Soc. Med. 79(3), 165-169 (1986).
50. McNeil BJ, Weichselbaum R, Pauker SG. Fallacy of the five-year survival in lung cancer. N. Engl. J. Med. 299(25), 1397-1401 (1978).
51. Goligher JC. Judging the quality of life after surgical operations. J. Chronic Dis. 40, 631-633 (1987).
52. Torrance GW. Measurement of health state utilities for economic appraisal. J. Health Econ. 5(1), 1-30 (1986).
53. de Haes JCJM, Stiggelbout AM. Assessment of values, utilities and preferences in cancer patients. Cancer Treat.Rev. 22, 13-26 (1996).
54. Stiggelbout AM, Kiebert GM, Kievit J, Leer JWH, Habbema JDF, de Haes JCJM. The 'utility' of the time trade-off method in cancer patients: Feasibility and proportional trade-off. J. Clin. Epidemiol. 48, 1207-1214 (1995).
55. Van der Donk J, Levendag PC, Kuijpers AJ et al. Patient participation in clinical decision-making for treatment of T3 laryngeal cancer: A comparison of state and process utilities. J. Clin. Oncol. 13, 2369-2378 (1995).
56. Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, Ciampi A, Till JE, Boyd NF. The measurement of patients' values. Med. Decis. Making 2, 449-462 (1982).
57. Rutten-van Mölken MP, Bakker CH, van Doorslaer EK, van der Linden S. Methodological issues of patient utility measurement: Experience from two clinical trials. Med. Care 33, 922-937 (1995).
58. Morrison GC, Neilson A, Malek M. Improving the sensitivity of the time trade off method: Results of an experiment using chained TTO questions. Department of Economics Discussion Paper No.98/22, University of Nottingham: Nottingham, UK, (1998).
59. Stalmeier PFM. Discrepancies between chained and classic utilities induced by anchoring with occasional adjustments. Med. Decis. Making 22, 53-64 (2002).
60. Jansen SJ, Stiggelbout AM, Wakker PP et al. Patients' utilities for cancer treatments: a study of the chained procedure for the standard gamble and time tradeoff. Med. Decis. Making 18, 391-399 (1998).
61. Froberg DG, Kane RL. Methodology for measuring health state preferences-III: Population and context effects. J Clin. Epidemiol, 42(6), 585-592 (1989).
62. Tversky A, Kahneman D. The framing of decisions and the psychology of choice. Science 211, 453-458 (1981).
63. Kahneman, Tversky A. The psychology of preference. Sci. Am. 246, 160-173 (1982).
64. Dolan P. Modelling valuations for health states: the effect of duration. Health Pol. 38, 189-203 (1996).
65. Cook J, Richardson J, Street A. Cost utility analysis of treatment options for gallstone disease: Methodological issues and results. Health Econ. 3, 157-168 (1994).
66. Bleichrodt H, Johannesson M. An experimental test of constant proportional tradeoff and utility independence. Med. Decis. Making 17, 21-32 (1996).
67. Llewellyn-Thomas HA, Thiel EC, McGreal MJ. Cancer patients' evaluations of their current health states: the influence of expectations, comparisons, actual health status and mood. Med. Decis. Making 12, 115-122 (1992).
68. Llewellyn-Thomas HA, Sutherland HJ, Thiel EC. Do patients evaluations of a future health state change when they actually enter that state? Med. Care 31, 1002-1012 (1993).
69. de Boer AG, Stalmeier PF, Sprangers MA et al. Transhiatal versus extended transthoracic resection in esophageal carcinoma: patients' utilities and treatment preferences. Br. J. Cancer 86(6), 851-857 (2002).
70. Brazier J. Roberts J. Deverill M. The estimation of a preference-based measure of health from the SF-36. J.Health Econ. 21(2), 271-292 (2002).